3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
1
Solid Tumor
1
Neoplasms
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Biliary Tract Neoplasms
1
Bile Duct Neoplasms
1
Interventions
Gemcitabine
24
Cisplatin
14
Capecitabine
12
Oxaliplatin
11
Fluorouracil
11
Leucovorin
7
Irinotecan
7
Radiotherapy
5
durvalumab
4
Photochemotherapy
3
Magnetic Resonance Spectroscopy
3
Long-Term Synaptic Depression
3
Erlotinib Hydrochloride
3
Cholangiopancreatography, Endoscopic Retrograde
3
Carboplatin
3
trifluridine tipiracil drug combination
2
regorafenib
2
olaparib
2
ceralasertib
2
Stents
2
Sorafenib
2
Radiosurgery
2
Radiofrequency Ablation
2
Liver Transplantation
2
Filgrastim
2
Dihematoporphyrin Ether
2
1-phenyl-3,3-dimethyltriazene
2
zimberelimab
1
tivozanib
1
titanium silicide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Bile Duct Neoplasms
×
ARRY-334543
×
Clear all
NCT03093870
2021-08-03
TreeTopp
ASLAN Pharmaceuticals
Phase 2/3
Completed
151 enrolled
18 charts